The PRECISION-T trial shows that ORCA-T, a precisely formulated graft with high regulatory T-cell and low conventional T-cell doses, dramatically improves chronic GVHD-free survival by 50 percentage points versus standard of care. This demonstrates that re-engineering the cell graft itself is a powerful prophylactic strategy beyond pharmacological intervention.

Trials adding an investigational drug to steroids for initial chronic GVHD treatment consistently fail because many patients respond to steroids alone in the short term. This early efficacy masks the new drug's potential benefit, leading to failed studies (e.g., with mycophenolate, ibrutinib, belumosudil) and a push towards new trial designs.

Contrary to common assumptions, standard initial steroid therapy is ineffective for the vast majority of adult ITP patients. Approximately 80% progress to chronic disease, highlighting the urgent need for more effective first- and second-line therapies to alter the disease course.

Despite being an FDA-approved option, ibrutinib is now rarely used for chronic GVHD. Real-world data reveals lower efficacy than in its pivotal trial (45% vs 60% ORR) and a high rate of discontinuation due to toxicity (42%). This demonstrates how newer agents with better risk-benefit profiles can quickly displace established therapies in clinical practice.

The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

Despite many approved drugs for Inflammatory Bowel Disease (IBD), single-mechanism therapies consistently fail to get more than 30% of patients into remission. This recognized "therapeutic ceiling" exists because IBD is a multi-faceted disease. The next breakthrough requires attacking multiple biological pathways simultaneously with combination drugs to achieve significantly higher efficacy.

Despite significant progress in managing symptoms for autoimmune conditions, very few treatments fundamentally alter the disease's course. The major unmet needs and investment opportunities lie in therapies that can induce remission or target common underlying pathologies like fibrosis, moving beyond mere symptom relief.

Despite widespread adoption, post-transplant cyclophosphamide (PTCI) is not the universal standard of care, particularly in myeloablative transplants. Phase 3 trials like PROGRESS-2 failed to show its superiority, leading to continued use of calcineurin inhibitor/methotrexate in nearly half of matched-related donor cases, highlighting a key split in clinical practice.

In rare NRG1-fusion positive cancers, targeted therapy shows a modest 29% objective response rate, below the typical 40% benchmark for accelerated approval. However, the median duration of response is nearly a year (and 1.5 years in naive patients), making it a highly effective, life-altering therapy for responders. This highlights duration, not just rate, as a key efficacy metric.